A conclusion highlighted by Cox and colleagues is that LOX expression in ER– breast cancer could be a useful biomarker for increased bone metastasis risk as well as for the identification of patients for bisphosphonate treatment in the adjuvant setting. Here, LOX is linked to breast cancer.